› Forums › General Melanoma Community › Interferons and cancer
- This topic has 9 replies, 3 voices, and was last updated 12 years, 1 month ago by
washoegal.
- Post
-
- April 11, 2013 at 8:31 pm
Articles from journal. Puzzled that they are describing interferon in this way. Don't I understand that interferon is not a great success in melanoma? Perhaps I got this wrong?
___________________________________________________________________________________________________________________
Articles from journal. Puzzled that they are describing interferon in this way. Don't I understand that interferon is not a great success in melanoma? Perhaps I got this wrong?
___________________________________________________________________________________________________________________
Interferons and Their Antitumor Properties Leonidas C. Platanias Journal of Interferon & Cytokine Research, Vol. 33, No. 4, April 2013: 143-144. http://online.liebertpub.com/doi/abs/10.1089/jir.2013.0019?ai=sk&ui=1i85m&af=T#utm_source=ETOC&utm_medium=email&utm_campaign=jir ------------------------------------------------------------------------ Biological Rationale and Clinical Use of Interferon in the Classical BCR-ABL-Negative Myeloproliferative Neoplasms Brady L. Stein and Ramon V. Tiu Journal of Interferon & Cytokine Research, Vol. 33, No. 4, April 2013: 145-153. http://online.liebertpub.com/doi/abs/10.1089/jir.2012.0120?ai=sk&ui=1i85m&af=T#utm_source=ETOC&utm_medium=email&utm_campaign=jir ------------------------------------------------------------------------ Immunomodulatory Effects of Interferons in Malignancies Joseph Bekisz, Yuki Sato, Chase Johnson, Syed R. Husain, Raj K. Puri, and Kathryn C. Zoon Journal of Interferon & Cytokine Research, Vol. 33, No. 4, April 2013: 154-161. http://online.liebertpub.com/doi/abs/10.1089/jir.2012.0167?ai=sk&ui=1i85m&af=T#utm_source=ETOC&utm_medium=email&utm_campaign=jir ------------------------------------------------------------------------ Interferons as Inducers of Apoptosis in Malignant Cells Kevin P. Kotredes and Ana M. Gamero Journal of Interferon & Cytokine Research, Vol. 33, No. 4, April 2013: 162-170. http://online.liebertpub.com/doi/abs/10.1089/jir.2012.0110?ai=sk&ui=1i85m&af=T#utm_source=ETOC&utm_medium=email&utm_campaign=jir ------------------------------------------------------------------------ Interferon-γ-Induced Necrosis: An Antitumor Biotherapeutic Perspective Siddharth Balachandran and Gregory P. Adams Journal of Interferon & Cytokine Research, Vol. 33, No. 4, April 2013: 171-180. http://online.liebertpub.com/doi/abs/10.1089/jir.2012.0087?ai=sk&ui=1i85m&af=T#utm_source=ETOC&utm_medium=email&utm_campaign=jir ------------------------------------------------------------------------ STAT Activation in Malignancies: Roles in Tumor Progression and in the Generation of Antineoplastic Effects of IFNs Ben X. Wang, Leonidas C. Platanias, and Eleanor N. Fish Journal of Interferon & Cytokine Research, Vol. 33, No. 4, April 2013: 181-188. http://online.liebertpub.com/doi/abs/10.1089/jir.2012.0154?ai=sk&ui=1i85m&af=T#utm_source=ETOC&utm_medium=email&utm_campaign=jir ------------------------------------------------------------------------ Regulation of snoRNAs in Cancer: Close Encounters with Interferon Shreeram C. Nallar and Dhananjaya V. Kalvakolanu Journal of Interferon & Cytokine Research, Vol. 33, No. 4, April 2013: 189-198. http://online.liebertpub.com/doi/abs/10.1089/jir.2012.0106?ai=sk&ui=1i85m&af=T#utm_source=ETOC&utm_medium=email&utm_campaign=jir ------------------------------------------------------------------------ A Death-Promoting Role for ISG54/IFIT2 Nancy C. Reich Journal of Interferon & Cytokine Research, Vol. 33, No. 4, April 2013: 199-205. http://online.liebertpub.com/doi/abs/10.1089/jir.2012.0159?ai=sk&ui=1i85m&af=T#utm_source=ETOC&utm_medium=email&utm_campaign=jir ------------------------------------------------------------------------ The Schlafen Family of Proteins and Their Regulation by Interferons Evangelos Mavrommatis, Eleanor N. Fish, and Leonidas C. Platanias Journal of Interferon & Cytokine Research, Vol. 33, No. 4, April 2013: 206-210. http://online.liebertpub.com/doi/abs/10.1089/jir.2012.0133?ai=sk&ui=1i85m&af=T#utm_source=ETOC&utm_medium=email&utm_campaign=jir ------------------------------------------------------------------------ Hope and Fear for Interferon: The Receptor-Centric Outlook on the Future of Interferon Therapy Serge Y. Fuchs Journal of Interferon & Cytokine Research, Vol. 33, No. 4, April 2013: 211-225. http://online.liebertpub.com/doi/abs/10.1089/jir.2012.0117?ai=sk&ui=1i85m&af=T#utm_source=ETOC&utm_medium=email&utm_campaign=jir
- Replies
-
-
- April 13, 2013 at 6:47 pm
I saw nothing in the abstracts, at least, the referred to melanoma specifically. Interferon is used for a variety of aliments.
Regarding the other post "Interferon – the "Gold Standard for Stage 3" I believe that's because it's the ONLY approved treatment.
-
- April 13, 2013 at 6:47 pm
I saw nothing in the abstracts, at least, the referred to melanoma specifically. Interferon is used for a variety of aliments.
Regarding the other post "Interferon – the "Gold Standard for Stage 3" I believe that's because it's the ONLY approved treatment.
-
- April 13, 2013 at 6:47 pm
I saw nothing in the abstracts, at least, the referred to melanoma specifically. Interferon is used for a variety of aliments.
Regarding the other post "Interferon – the "Gold Standard for Stage 3" I believe that's because it's the ONLY approved treatment.
- You must be logged in to reply to this topic.